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Since it was first reported a few decades ago, RNA interference (RNAi) has become a widely used 21 
research tool for cellular genetic knockdown. However, its instability and susceptibility to 22 
enzymatic degradation has prevented its widespread adoption for use in clinic, and thus major 23 
research efforts are directed at seeking methods to protect the fragile RNA payload during 24 
delivery. Here, we report the use of a metal-organic framework (MOF) to load, protect, and deliver 25 
small interfering ribonucleic acids (siRNA). We confirmed protection of MOF-internalized siRNA 26 
from enzymatic degradation. Furthermore, through combined encapsulation of siRNA in the 27 
MOF with a variety of additional cofactors (proton sponge, KALA peptide and NH4Cl) we show 28 
that endosomal retention can be evaded and we ensure the efficacy of gene knockdown. In vitro 29 
studies after siRNA/MOF complexation demonstrated consistent levels of knockdown of up to 30 
27%. We use structured illumination super-resolution microscopy (SIM) to study the endocytic 31 
uptake of the complex. Overall, we demonstrate the potential of these highly porous and 32 
biodegradable materials as a means to improve both efficacy and efficiency of future gene 33 
therapies.   34 
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Every year, more than 14 million people are diagnosed with cancer, and more than 1 in 3 people will 35 
develop some form of cancer during their lifetime.1,2  Although there are great advances in terms of 36 
diagnosis and treatment, cancer remains a key societal health concern. Depending on cancer type and 37 
stage, common treatments include surgical resection, chemo- and radiotherapy.3 The key to success of 38 
these treatments lies in early detection, screening, and improvements in the treatment technologies.4 In 39 
many cases, however, complete tumor resection is not feasible due to the invasive nature of required 40 
procedures, making local recurrence inevitable. In addition, many patients are not suitable for surgery 41 
due to co-morbidities or proximity of tumors to vital structures. This is particularly critical for hard-to-42 
treat cancers such as ovarian, malignant mesothelioma, triple-negative breast, and pancreatic cancer – 43 
where five-year survival rates have not improved in the last 20 years and are still around 10%.5,6 For 44 
these cancers, common treatments are not successful and there is an imperative need to develop novel 45 
therapeutic approaches.  46 
One such approach is the use of small interfering ribonucleic acids (siRNAs) for gene knockdown 47 
expression of key cancer driver genes, which has received great attention over recent years.7–9 This 48 
method is attractive because it i) has a high efficiency of knockdown, ii) is highly specific and thus 49 
exhibits minimal off-target effects, and iii) has a lack of systemic toxicity and immunoreactivity.10 50 
Various medical diseases in addition to cancer, including neurological disorders and viral infections, may 51 
in the future benefit from siRNA gene therapies.11,12 siRNA is a double-stranded RNA fragment typically 52 
twenty-one to twenty-three nucleotides in length that can code for a particular cellular gene, cleaved from 53 
endogenously expressed long double-stranded RNAs (dsRNAs).13 Synthetically-created siRNAs have 54 
potential as inhibitors of various disease-associated genes, bypassing the first step of endogenous 55 
cleavage, and allowing for the creation of a platform technology with any genetic sequence. The 56 
mechanism for siRNA delivery and subsequent gene knockdown is universal for any selected sequence, 57 
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giving it targeted therapeutic potential.11 This is in contrast to drugs currently used in cancer therapies – 58 
including doxorubicin, 5-fluorouracil or docetaxel – which may act on multiple pathways.14 59 
Although siRNA therapy has potential to benefit patients with cancer, the main limitation is its lack 60 
of stability and ease of degradation by native biological enzymes.15,16 In addition, while non-encapsulated 61 
small molecule drugs can enter the cell cytoplasm directly through the plasma membrane, macromolecule 62 
delivery into cytoplasm is challenging. To overcome this problem, researchers have altered the chemical 63 
structure of siRNAs through modifications to the phosphodiester, sugar backbone, or have changed bases 64 
in the sequence.17,18 There has been some success with chemical modifications to siRNAs,19,20 such as 65 
improving duplex stability and conferring nuclease resistance by replacing the 2’-hydroxyl of the ribose; 66 
modification of a few residues has been generally well tolerated.21 However, chemical modifications are 67 
sequence dependent and can require tailoring for different siRNAs. Additionally, chemical modification 68 
tends to lower the therapeutic efficacy of the siRNAs upon cytosolic delivery. An alternative approach 69 
is the incorporation, and thus protection, of siRNAs as a payload within polymers or nanoparticles.22–24  70 
Some examples are organic delivery vehicles, such as liposomes or nanoparticles, to carry siRNAs into 71 
the cell, protecting it from degradation in the extra-cellular space. However, liposomes tend to 72 
accumulate in the reticuloendothelial system16 and some formulations of nanoparticles can only achieve 73 
low loading capacities due to the low negative charge and intrinsic stiffness of double-stranded 74 
siRNA.22,25,26  75 
In this context, metal−organic frameworks (MOFs), a class of porous self-assembled materials 76 
composed of metal ions/clusters connected by organic linkers, are one of the most promising materials 77 
for biomedicine.27–31 There are currently more than 84,000 MOF structures in the Cambridge Structural 78 
Database and the diversity that MOFs offer is of particular interest for siRNA delivery. Others have 79 
utilized MOFs for the delivery of siRNAs and other biomacromolecules, such as CRISPR/Cas9 80 
machinery.29,32,33 However, in these cases, the selected biocompatible MOFs do not contain pore 81 
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dimensions large enough to allow for internally adsorbed siRNAs.29,33 Additionally, in the case with 82 
CRISPR/Cas9, the synthesis had to be altered to build the framework (ZIF-8) around the 83 
biomacromolecule machinery,32 limiting in principle the scope of frameworks feasible with this method, 84 
as well as incorporating a zinc-based moiety that has been shown in literature to be toxic even at low 85 
concentrations.34 By selecting appropriate MOFs that can provide large pore sizes, we allow for the 86 
encapsulation of macromolecules and their subsequent protection, increasing their bioavailability within 87 
the tumor whilst avoiding off-target toxicity.27 Among the different MOFs, we and others have utilized 88 
zirconium-based MOFs (Zr-MOFs) for a variety of reasons.35,36 They have been shown to be stable in 89 
water, a useful characteristic for loading the MOFs with a biological payload, and demonstrate a lack of 90 
toxicity and high thermal, mechanical, and chemical stabilities. Importantly, however, these MOFs have 91 
no long-term stability in biological solvents where their breakdown prevents potentially in vivo 92 
accumulation.31 In this work, we bring together a combination of multidisciplinary tools to develop a 93 
MOF-based platform for the encapsulation of siRNAs and its successful delivery into cells. We explore 94 
the mechanism through which the MOF is able to protect the siRNA from degradation in the extra-95 
cellular space, and also how the siRNA is released from the MOF and delivered to the cytosol to become 96 
active in the cell. We also prove that the system leads to the specific knockdown of a targeted gene. 97 
Design of cell system and corresponding siRNAs 98 
We utilized a previously designed HEK 293 cell line40 (referred here as HEK 293-mC) based on the 99 
commercially available T-REx Flp-In system, where mCherry fluorescence expression can be induced 100 
using doxycycline or tetracycline (dox or tet). To coordinate an siRNA sequence with the mCherry gene 101 
genetically engineered into the HEK 293-mC cells, we designed a custom siRNA sequence. We sought 102 
a sequence that limited off-target effects and effectively coded for the inducibly expressed mCherry 103 
protein. From the genetic code of the mCherry used, 5 out of 32 21-nucleotide length sequences were 104 
identified as promising candidates due to their low GC content (<50%) and no stretches of greater than 105 
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4 T or A basepairs, as literature demonstrated these considerations improve activity.41,42 We evaluated 106 
these 5 siRNAs loaded on lipofectamine qualitatively using microscopy and western blot analysis to 107 
determine whether there was any knockdown in intracellular mCherry signal; Table S1, in the 108 
Supplementary Information, lists the 5 identified siRNAs. Figure 1a shows optical microscopy images 109 
of 4 siRNA control conditions after they are incubated with HEK 293-mC cells, some of which are 110 
doxycycline-induced; Figure S1 shows the quantitative intensity analysis of the microscope images. 111 
When not induced (i.e. -dox in Fig. 1a), the cells show no visible fluorescence, whereas when induced 112 
(i.e. +dox) and not siRNA treated (“no treatment”), the cells fluoresce. To demonstrate that only a specific 113 
targeted siRNA sequence leads to knockdown of the mCherry fluorescence, we used a “scrambled 114 
siRNA.” Differences in brightness levels between cells treated with scrambled siRNAs and those with 115 
no treatment were not significant, verifying that the random sequence has no effect on mCherry 116 
knockdown. When reverse transfecting the 5 different custom siRNAs with the cells in Figure 1b, the 117 
brightness of the red signal varies between different siRNA strands. This indicates that siRNA 2, 3, 17, 118 
28, and 29 had differential knockdown efficiencies for mCherry, with siRNA 3 and 28 appearing to be 119 
most effective. This is clear in the western blot (Fig. 1c), where bands for anti-RFP antibody for samples 120 
3 and 28 are noticeably less intense than any other band of mCherry induced cells. A Ponceau stain shows 121 
equal loading of all samples (Fig. 1d). For all subsequent experiments, we utilized siRNA sample 3 as a 122 




Figure 1 | siRNA design and testing on doxycycline-induced HEK 293-mC cells. a, Optical Microscopy of HEK 293 125 
T-Rex Flp-In-mCherry cells when induced with doxycycline (+dox) and when not induced with doxycycline (-dox) 126 
for cells under treatment with scrambled siRNA (top) or without any siRNA (bottom) and lipofectamine. 127 
b, Corresponding images of doxycycline induced cells (+dox) transfected with five different siRNA sequences 128 
coding for the mCherry gene. c, western blot using anti-RFP antibody for the same conditions as depicted in (a) 129 
and (b). Bands represent relative levels of mCherry protein within cells post transfection. d, Ponceau stain 130 
evaluating equal effectiveness of loading. 131 
Loading of siRNAs into MOF and characterization 132 
In order to select an optimal Zr-MOF, we performed molecular simulations to find a structure with a 133 
porosity compatible with this specific macromolecule; this also allows us to gain insights into how the 134 
presence of one double-stranded siRNA 3 molecule affects the energetics of the encapsulating MOF 135 
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system. We considered NU-1000 (Zr6-based MOF composed of Zr6(μ3-OH)4(μ3-O)4(OH)4(OH2)4 nodes 136 
and pyrene-based linkers [TBAPy4−, 1,3,6,8-tetrakis(p-benzoate)pyrene];43 NU: Northwestern 137 
University) based on previous experience and the possibility of tuning the particle size into the nm range 138 
(which we term nNU-1000). We have previously performed cell toxicity assessments and degradation 139 
studies in phosphate buffered saline (PBS) for this particular MOF that verify its biocompatibility and 140 
use for these biological applications.31 We have also verified by proton NMR that the DMF used during 141 
the solvothermal synthesis of the MOF, which could negatively impact future biological applications, is 142 
completely removed during the purification and activation of the MOF (Figure S2, Supplementary 143 
Information).  Additionally, the porosity of nNU-1000 is sufficiently large to allow the encapsulation of 144 
siRNA 3 within its 3 nm diameter and hexagonal mesoporous channels. Figure 2a shows an energy 145 
minimized final configuration of an siRNA molecule in nNU-1000 pore model, with a favorable binding 146 
energy of -878 kJ/mol; the energies of nNU-1000 with siRNA compared with the isolated systems are 147 
located in Table S2, in the Supplementary Information. It indicates that there is sufficient free volume 148 
for the siRNA and NU-1000 components to pack without distortions as is verified with the favorable 149 
(negative) energy, suggesting a thermodynamic preference for the siRNA molecule to be located inside 150 
the NU-1000 pore channel.   151 
We then loaded siRNAs into the MOF nanoparticles – nNU-1000. Figure 2b shows the powder X-152 
ray diffraction (PXRD) patterns of nNU-1000 and loaded samples and the comparison with the simulated 153 
pattern. The nNU-1000 was activated at 100˚C for 3 days to ensure that all potential solvent inside the 154 
pore structure was removed. The main peaks are preserved but some minor ones are lost when compared 155 
with the calculated pattern; this is compatible with the small particle size of nNU-1000. We then soaked 156 
nNU-1000 in RNase free water at the same MOF concentration as our siRNA-loaded sample (20 mg/mL) 157 
and observed excellent agreement with the PXRD pattern of the activated nNU-1000. However, the 158 
loading of siRNAs in nNU-1000 (siRNA@nNU-1000) led to a decrease in the intensity of the major 159 
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peaks. This is consistent with a notion that the siRNAs are adsorbed inside the porous MOF cavity, 160 
causing a decrease in the contrast between phases (i.e. the framework and the empty or filled porosity) 161 
and therefore a decrease of the peak intensity. The amount of siRNA loaded, measured from the liquid 162 
supernatant, was approximately 150 pmol/mg of nNU-1000, as quantified by an RNA-specific 163 
fluorescence marker.   164 
165 
Figure 2 | Encapsulation of siRNAs with NU-1000. a. schematic lateral and top-view of a section of the NU-1000 166 
pore channel with one double-stranded siRNA molecule (red and blue intertwined space filling structure). 167 
b. powder X-ray diffraction (PXRD) patterns of simulated NU-1000, activated nNU-1000, nNU-1000 soaked in 168 
water and siRNA loaded nNU-1000. c. fluorescence-lifetime imaging microscopy (FLIM) analysis of different 169 
systems. Data are shown in box-and-whiskers style, where “box” represents 1st quartile, median, and 3rd quartile, 170 
and “whiskers” (lines) represent minimum and maximum values. Averages are represented by the red dots. 171 
Individual data points are shown in faint colored circles with outliers as grey circles. 15 lifetime images were 172 
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acquired per condition. Statistical analysis was carried out using one-way ANOVA followed by Sidak’s Multiple 173 
Comparisons test (* P<0.05). d. 20% TBE polyacrylamide gel stained with PAGE GelGreen for the enzyme 174 
degradation protection analysis of different systems. A dsRNA ladder on far right of gel gives location of 21 175 
nucleotide length fragments. White arrows indicate the presence of non-degraded siRNAs. 176 
As mentioned above, enzymatic degradation is one of the major drawbacks in siRNA therapy. The 177 
question of whether the siRNAs are located inside the MOF’s porosity or outside on the external surface 178 
– or in both locations – is therefore critical for its efficient transfection. We first evaluated the localization 179 
of the siRNA through fluorescence lifetime imaging microscopy (FLIM). The fluorescence lifetime is 180 
sensitive to the micro-environment of a fluorescent molecule44 and can provide an indirect readout on 181 
intermolecular interactions on the scale of a few nanometers. We used time correlated single photon 182 
counting (TSCPC) to quantify FLIM signals. Loading MOFs with fluorescently labeled siRNAs results 183 
in a drop on lifetime of the intrinsic fluorescence emission from the MOF material because of energy 184 
transfer from the dye to the MOF scaffold. We loaded nNU-1000 with a high concentration of siRNAs, 185 
using both tagged and non-tagged varieties. We then reacted these samples with an enzyme that can 186 
cleave siRNA of 21 nucleotides (nts) in length. Since the enzyme is too large to enter into the porous 187 
MOF structure, it will be able to degrade only the siRNAs that are exposed on the external surface of the 188 
MOF. Figure 2c shows the fluorescence lifetimes for five experimental conditions: nNU-1000 only; 189 
siRNA-, untagged or tagged, loaded nNU-1000; and enzyme-reacted siRNA-, untagged or tagged, loaded 190 
nNU-1000. The fluorescence lifetime for the MOF alone is 5497 ± 60 ps. This value decreases slightly 191 
but not significantly to 5352 ± 80 ps for the untagged-siRNA@nNU-1000, indicating that without the 192 
fluorophore, there is no energy transfer and therefore no effect on the MOF’s fluorescence lifetime. The 193 
enzyme reacted with the untagged-siRNA@nNU-1000 also shows a negligible change in lifetime (5492 194 
± 80 ps). However, the lifetime of the tagged-siRNA@nNU-1000 drops significantly (P<0.0001) to 4718 195 
± 80 ps, indicating that the MOF fluorescence is quenched due to a FRET- (Foerster Resonance Energy 196 
Transfer) like process between the labeled siRNA and the MOF scaffold it occupies. In the case of the 197 
enzyme-reacted tagged-siRNA@nNU-1000, we observed a statistically significant increase (P<0.05) up 198 
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to 5023 ± 70 ps. This noticeable increase in lifetime from the non-enzyme reacted to enzyme-reacted 199 
structure of ca. 300 ps suggests that some level of siRNA degradation is occurring. In order for the 200 
enzyme to degrade the siRNA, some siRNAs must be located externally on the MOF’s surface. However, 201 
the more prominent decrease in lifetime of ca. 500 ps between the nNU-1000 only and the tagged-202 
siRNA@nNU-1000 with enzyme (P<0.001) suggests that the majority of the siRNAs are loaded in the 203 
internal porosity of nNU-1000. 204 
To further analyze the capacity of nNU-1000 to protect siRNA, we designed an enzyme protection 205 
assay. Figure 2d shows the presence of the siRNA, measured on a gel, after exposure to the enzyme 206 
described above. As a control, we observed that the 21 nt band in the gel for the naked, unprotected, 207 
siRNA disappears when exposed to the enzyme, confirming that this enzyme cleaves siRNA sequences 208 
of this length. We also verified that nNU-1000 would not show a false positive band on the gel at the 21 209 
nt siRNA location; most of the MOF residue remaining post-purification gets trapped higher up on the 210 
gel, with bright and smeared bands at around 80 nt and above, as marked by the ladder. In addition, there 211 
is no change in the gel pattern for nNU-1000 reacted with enzyme, demonstrating that the enzyme would 212 
not cleave any MOF components to a similar size as the 21 nt band. After purification of the siRNAs 213 
from the siRNA@nNU-1000 sample, both with and without exposure to the enzyme, bands are present 214 
at the 21 nt location, demonstrating the capability of nNU-1000 to protect the siRNAs from enzymatic 215 
degradation.   216 
In vitro effect of siRNA on mCherry cell line 217 
With the characterized siRNA@MOF system, we aimed to quantify the signal knockdown and efficacy 218 
in vitro. We activated the inducible HEK 293-mC cell line with tetracycline and incubated it with various 219 
controls along with the siRNA@NU-1000. Figure 3a shows the results of the mCherry expression levels 220 
normalized to induced HEK 293-mC cells; Table 1 highlights the first quartile, median, third quartile, 221 
and interquartile range (IQR) values for the different experiments. We can first confirm that these cells 222 
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do not express mCherry when not induced – in this case expression levels are around 1.2%. This figure 223 
also demonstrates the ineffectiveness of the naked siRNAs when added to the cells, as mCherry 224 
expression levels did not deviate significantly from those of untreated induced cells. The positive control, 225 
siRNA@lipofectamine, shows a significant decrease of 40% in signal compared to the normalized signal 226 
from induced HEK 293-mC cells. We also verified that the nNU-1000 did not by itself affect cellular 227 
expression levels of mCherry, as the mean value stays near 100%. Interestingly, when we added the 228 
siRNA@nNU-1000 complex, we observed a wide range of results. At times, there was no change in the 229 
mCherry expression and at other times the mCherry expression would be nearly as low as the positive 230 
control siRNA@lipofectamine. In other words, whereas the IQR (i.e. the box height) values for the 231 
previous cases was rather low, in the range of 5.7 and 9.4, it significantly increased for siRNA@NU-232 
1000 up to 26.5 (i.e. 219% increment compared to siRNA@lipofectamine). To understand this increase 233 
in the variability of mCherry expression levels, we utilized an siRNA tagged with a fluorophore at 647 234 
nm to assess the internalization of the siRNA@nNU-1000 complex in the HEK 293-mC cells. Figure 235 
3b shows the fluorescence of Alexa Fluor 647, representing the quantity of siRNAs, normalized to the 236 
positive control. As expected, we found minimal fluorescence in normal non-induced cells and induced 237 
cells, both without the addition of siRNAs. The observed signal is attributed to auto-fluorescence with 238 
no statistical difference between normal non-induced cells, induced cells, cells with naked siRNA added 239 
or cells with nNU-1000 only added. This confirms that no siRNA is present inside any of the cells. 240 
siRNA@nNU-1000 was taken up into cells nearly as efficiently as siRNA@lipofectamine, but was not 241 
as effective at knocking down mCherry expression. Since siRNA must be in the cytoplasm to be effective 242 
in its signal knockdown pathway, we hypothesized that the inconsistent and variable levels of mCherry 243 
gene knockdown are caused by siRNA@NU-1000 complex entrapment and degradation in endosomes, 244 




Figure 3 | In vitro performance of siRNAs loaded in NU-1000. a. mCherry expression level in HEK 293-mC cells as 247 
quantified by flow cytometry after 24 h incubation, b. Alexa Fluor 647 fluorescence of siRNA tagged, as quantified 248 
by flow cytometry and normalized to positive control, siRNA@lipofectamine and c. comparison of mCherry 249 
expression level in HEK 293-mC cells when using different co-factors. Plots are shown in box-and-whiskers style, 250 
where “box” represents 1st quartile, median, and 3rd quartile, and “whiskers” (lines) represent minimum and 251 
maximum values; averages are represented by the red dots. Individual data points are shown in faint colored 252 
circles with outliers as grey circles. Each condition was run with a minimum of 9 replicates with some conditions 253 
having up to 24 replicates. Statistical significance was calculated through one-way analysis of variance (one-way 254 

























Table 1 | In vitro performance of siRNAs loaded in NU-1000. Comparison between 1st quartile (Q1), 3rd quartile 264 
(Q3), and the interquartile range (IQR) for the normalised mCherry expression level in HEK 293-mC cells as 265 
quantified by flow cytometry. Each condition was run with a minimum of 9 replicates with some conditions having 266 













































































   
   










   
   











   
   













   
   






Q1 1 97.2 104.7 57.3 98.7 83.9 93.6 78.3 68.6 78.1 66.8 
Median 1.1 98.7 109.3 63 102.3 91.4 94.3 78.9 75.3 81.4 79.4 
Q3 1.6 103.7 114.1 65.6 104.4 110.4 95.1 83.4 79.7 89.1 82.2 
IQR 0.6 6.5 9.4 8.3 5.7 26.5 1.6 5.1 11.1 11 15.4 
 268 
To test the hypothesis of siRNA@NU-1000 entrapment in endosomes, we added to the siRNA@nNU-1000 269 
complex various factors including proton sponges or membrane opening peptides that are able to either break or 270 
open endosomes.24,45,46 We used Proton-Sponge® (PS), the amphipathic KALA peptide, and ammonium chloride 271 
(NH4Cl). First, we used FLIM on an Oregon Green 488-conjugated dextran – with the size that can enter through 272 
clathrin-mediated endocytosis, comparable to the pathway of entry that our nNU-1000 MOF uses – to quantify the 273 
capability of these endosomal release factors to avoid endosomal entrapment. Fluorescence lifetime increased 274 
significantly with pH (Figure S3), These results suggest that the cofactors PS and NH4Cl are acting in a mechanism 275 
that is increasing the vesicular pH from its normal value, whereas KALA, on the contrary, a cell-penetrating 276 
peptide is not explicitly acting as a proton absorber. Figure 3c shows the results of the mCherry expression levels 277 
for these complexed systems compared to the untreated induced HEK 293-mC cells. We loaded approximately 278 
0.04 mg of the Proton Sponge® cofactor (~2.7 wt.% of the complex), 0.4 µg of the KALA cell penetrating peptide, 279 
and 0.1 µmol (or 5.3 µg) of ammonium chloride. We believe that the small cofactors can be on both the external 280 
surface and in the internal porosity, whereas KALA is on the external surface due to its large size. The use and 281 
incorporation of a cell-penetrating or targeting peptide and complexation of endosomal release cofactors to  our 282 
siRNA@MOF system is an element of novelty for this study. When the PS was added (siRNA@nNU-1000-PS), 283 
the average expression decreased to ca. 78% of the normal induced HEK 293-mC cells. Compared to the impact 284 
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on mCherry expression of the Proton-Sponge® or the nNU-1000 alone, with expression values of ca. 95 and 100%, 285 
respectively, this decrease is statistically significant (P<0.01 and <0.001, respectively). When using KALA 286 
(siRNA@nNU-1000-KALA), we observed a decrease in mCherry signal to ca. 73%. Interestingly, when we co-287 
loaded the MOF with both of these compounds (siRNA@nNU-1000-PS+KALA), we observed a reduction to ca. 288 
82%, a value that is not statistically different to those of siRNA@nNU-1000-PS and siRNA@nNU-1000-KALA. 289 
While literature suggested different mechanisms of action for these particular two cofactors, it was not known if 290 
there would be a more efficient response if both were included together. Our results indicate that there is not a 291 
cumulative effect of the two compounds. When we added a different compound, ammonium chloride, to the 292 
siRNA@MOF complex (siRNA@nNU-1000-NH4Cl), we observed mCherry expression at ca. 75% of the induced 293 
HEK 293-mC cell value. Regardless of the specific cofactor, when complexed together with the siRNA@nNU-294 
1000, they assisted in the gene knockdown capabilities of the system. The relatively high mCherry expression 295 
levels for all the systems, including lipofectamine positive control, with knockdown levels below 50% could be 296 
related to the long half-life of the protein. Importantly, we were able to reach, in some cases, knockdown effects 297 
on par with that of the positive control siRNA@lipofectamine.  298 
 299 
Super-resolution microscopy analysis of in vitro trends  300 
We performed experiments in vitro using structured illumination microscopy (SIM) 31,47 to get a visual picture of 301 
the uptake and release processes discussed. Figure 4 shows 3-color images of HEK 293-mC cells where we have 302 
labeled the early endosomes with an RFP marker. In addition, we incubated the cells with either naked Alexa Fluor 303 
647-tagged siRNA (Fig. 4a), Alexa Fluor 647-tagged siRNA@lipofectamine, the same positive control we used 304 
in the previous experiment (Fig. 4b); siRNA@nNU-1000 (Fig. 4c) and siRNA@nNU-1000-KALA (Fig. 4d). In 305 
all images, the tagged siRNAs can be visualized in red, the nNU-1000, when present, is colored in green and the 306 
early endosomes are shown in blue. We chose to stain the early endosomes as opposed to other cellular organelles 307 
in an attempt to visualize the point at which the siRNA@nNU-1000 complex dissociates from the endosome, as it 308 
must do this to effectively deliver the siRNA into the cytoplasm. As determined previously,31 nNU-1000 requires 309 
active transport to enter cells. It was thus expected that the systems with MOF would colocalize with the early 310 
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endosomes, whereas the naked siRNA and the siRNA@lipofectamine would not. In agreement with our 311 
observations from flow cytometry, we observe that little, if any, of the tagged siRNA signal is located 312 
intracellularly (Fig. 4a). When using siRNA@lipofectamine, we observed a large amount of tagged siRNA 313 
intracellularly – but not colocalized with the endosome (Fig. 4b). The lack of endosome colocalization is portrayed 314 
with the distinctive red marks in the cell. In the case of siRNA@nNU-1000, the complex directly overlaps with 315 
early endosomes, shown by white color indicative of 3-color overlap (Fig. 4c). Two specific instances of 3-color 316 
overlap are pointed out by the white arrows, indicating that both the siRNA and nNU-1000 are contained within a 317 
vesicle – meaning the siRNA would be unable to act with the RISC complex in the cytosol and gene knockdown 318 
would not occur. In the case of siRNA@nNU-1000-KALA, the white arrow highlights a position of 2-color 319 
overlap between the siRNA and nNU-1000, shown by the yellow color instead of white (Fig. 4d). This 320 
demonstrates an example of an siRNA not trapped within an endosome and able to bind with the RISC complex 321 
and initiate the RNAi pathway. The lack of white color (i.e. the 3-color overlap) in Figure 4d supports our 322 
hypothesis about the endosomal release factors helping the siRNA@nNU-1000 to evade endosomal retention, and 323 




Figure 4 | Representative SIM images of siRNA uptake into HEK 293-mC cells. Images of HEK 293-mC cells incubated with a, 326 
naked Alexa Fluor 647-tagged siRNA b, Alexa Fluor 647-tagged siRNA@lipofectamine c, Alexa Fluor 647-tagged siRNA@nNU-327 
1000 and d, Alexa Fluor 647-tagged siRNA@nNU-1000 KALA. Early endosomes stained in blue; Alexa Fluor 647-tagged siRNA 328 
in red; nNU-1000 in green. Blue channel taken with SIM; red and green channels taken in wide field. Cell outlines are shown 329 
by dashed white lines. Scale bars are 10 μm. The arrows indicate instances of two or three-color overlap.  330 
Conclusions 331 
In this study, we demonstrate the successful development and proof-of-concept efficacy of a Zr-based 332 
metal−organic framework, nNU-1000, that is able to load, protect, and deliver siRNA effectively in the 333 
cytoplasm to knockdown gene expression. We performed molecular simulations to select the MOF that 334 
favored internalization of the siRNA. We characterized the loading of the siRNAs into the MOF by 335 
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PXRD, where the broadening, decreased intensity, and elimination of some peaks indicated that the 336 
siRNAs interacted with the framework in a way that decreased the contrast of the peak intensity, as well 337 
as reduced the crystallinity. An enzyme degradation stability study demonstrated that the siRNAs were 338 
protected by the MOF, as relevant 21 nt bands were still observed on a polyacrylamide gel after 339 
enzymatic attack. We performed studies to elucidate the location of the siRNAs within or on the 340 
framework using fluorescence-lifetime imaging microscopy (FLIM). These results suggest that a 341 
negligible amount of siRNAs were located external on the MOF’s surface, thus the majority of the 342 
siRNAs were loaded within the internal porosity of the structure. In vitro studies at first suggested that 343 
the siRNA was able to enter the cell when carried by nNU-1000, but that efficacy was inconsistent. Based 344 
on the hypothesis that this was due to endosomal entrapment, we complexed the siRNA@MOF system 345 
with various factors – species that are able to open up endosomes through various mechanisms. By taking 346 
advantage of these factors, it was possible to observe consistent levels of knockdown. SIM images show 347 
representative examples of the trends we noted in the flow cytometry, and indicate instances along the 348 
endosomal uptake pathway at which the siRNA@MOF complex is able to separate from the early 349 
endosomes. To the best of our knowledge, this work is the first to utilize a large porous network to 350 
internally encapsulate siRNAs in sufficient quantities to achieve gene knockdown –150 pmol/mg MOF. 351 
The stability of the MOF material offers future advantages in long-term storage, while the tunability of 352 
the MOFs can allow further modifications to improve efficacy. Through this work, we show how the 353 
efficacy and efficiency of gene therapy can be improved with implementation of this highly porous 354 
material. 355 
Methods 356 
Materials. NU-1000 (also referred to as nNU-1000, 150 nm size) was obtained via synthesis published 357 
in previous protocols.48 Custom siRNA (sense strand 5’ – AAGGAGTTCATGCGCTTCAAG – 3’) and 358 
custom tagged siRNA (sense strand 5’ Alexa Fluor 647 tag), was ordered from Eurogentec. HEK 293 T-359 
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rex Flp-In cells were obtained from the ATCC and were modified with a T-REx insert as published in 360 
literature.40 They were cultured with Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich 361 
D5671), fetal bovine serum (FBS, Sigma-Aldrich F9665), 100× 200 mM L- glutamine (Life 362 
Technologies 25030024), penicillin and streptomycin (P-S, Life Technologies 15140122), hygromycin 363 
(Thermo Fisher, 10687010, 100 μg/mL final concentration), and blasticidin (Thermo Fisher, R21001, 15 364 
μg/mL final concentration). Phosphate-Buffered Saline (PBS, Sigma D8537) and 1x trypsin−EDTA (Life 365 
Technologies 25300054) were used. Trypan blue was purchased from Thermo Fisher (UK, 15250061). 366 
Opti-MEM™ Reduced Serum Medium GlutaMAX™ Supplement and Lipofectamine™ RNAiMAX 367 
Transfection Reagent were purchased from Thermo Fisher (51985034 and 13778030, respectively). All 368 
enzymes and gel ladders used were purchased from New England Biolabs. Novex 20% TBE 369 
polyacrylamide gel (EC63155BOX) and Hi-Density TBE Sample Buffer (LC6678, 5X) were bought 370 
from Thermo Fisher. A PAGE GelGreen™ Nucleic Acid stain was purchased from Biotium and the 371 
Zymo Oligo Clean & Concentrator™ kit was obtained from Cambridge Bioscience (UK, D4061). A 372 
Qubit™ microRNA Assay Kit was used (Thermo Fisher Q32880). Stains for endosomes were obtained 373 
from ThermoFisher (CellLight Early Endosomes-RFP BacMam 2.0, C10587). Proton-sponge® (99%) 374 
was obtained from Sigma Aldrich (158496), and the KALA peptide from AnaSpec (AS-65459). All 375 
chemicals and biochemicals used were of analytical grade. 376 
Molecular Mechanics Modeling. A simplified model of the siRNA and nNU-1000 system was 377 
constructed in the Materials Studio software package49 and was created from the NU-1000 378 
crystallographic data published previously.38 It consists of ten hexagonal rings of Zr-oxide nodes, 379 
extended ca. 160 Å along the channel. A number of structures were considered, each with different 380 
arrangements of the siRNA molecule inside the hexagonal channel of NU-1000. Bonded and non-bonded 381 
interactions between all framework atoms were described by the Universal Force Field (UFF),50 and the 382 
structures were optimized using the Forcite module in Materials Studio, using an algorithm that is a 383 
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cascade of the steepest descent, adjusted basis set Newton-Raphson, and quasi-Newton methods. To 384 
estimate the energy associated with the siRNA molecule in NU-1000, we calculated the total energy of 385 
the hexagonal channel containing the siRNA molecule (Echannel+siRNA) and subtracted the energies 386 
obtained from the isolated channel (Echannel) and siRNA molecule (EsiRNA) according to: Eads = 387 
Echannel+siRNA – Echannel – EsiRNA.  388 
X-Ray Diffraction. Room temperature powder XRD (PXRD) was performed on nNU-1000 loaded and 389 
unloaded samples using a Bruker-D8 theta/theta machine with CuKα1 (λ = 1.5405 Å) radiation and a 390 
LynxEye position sensitive detector in Bragg Brentano parafocusing geometry. Steps were performed 391 
for 2θ = 2˚ to 50˚. 392 
siRNA Adsorption and Subsequent Cofactor Addition. Samples of nNU-1000 were measured (1.5 393 
mg each), and mCherry-encoding siRNA was added in a ratio of 1:2 – tagged siRNA:untagged siRNA – 394 
for a total of 15 μL of 10 μM siRNA. The tag was an Alexa Fluor 647 on the 5’ end of the sense strand. 395 
RNase-free water was added to each such that the final concentration of MOF was 20 mg/mL, and all 396 
samples were incubated at 37°C for approximately 2.5 h. Some samples then had a subsequent cofactor 397 
addition. For Proton-Sponge®, the calculation was as follows: the amount of metal cluster sites in the 398 
MOF sample, in mol, was determined (approximated to one-third the mol of MOF calculated). Half of 399 
this molar amount of cluster sites was converted to g of Proton-Sponge® (PS). A solution of PS was then 400 
created such that 10 μL of this Proton-Sponge® solution was added to the respective sample. For KALA, 401 
10 μL of a 0.04 mg/mL solution in RNAse free water was added to the respective sample. For ammonium 402 
chloride, 10 μL of a 10 mM solution in RNAse free water was added to the sample. All samples were 403 
incubated for another hour at 37°C. After the 1 h incubation, the samples were centrifuged at 14000 rpm 404 
for 60 s, and the supernatant was removed. 405 
siRNA Qubit Quantification. To quantify the amount of siRNAs in a supernatant solution, we used the 406 
Qubit™ microRNA Assay Kit (ThermoFisher Q32880). All samples were purified with the Zymo Oligo 407 
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Clean & Concentrator™ kit prior to incubation with the Qubit™ Assay kit and measured with the 408 
Qubit™ Fluorimeter. 10 μL aliquot of each purified sample was used.   409 
siRNA Enzyme Degradation Stability Analysis. 5 mg of nNU-1000 were incubated with 75 μL of 10 410 
μM untagged siRNA. RNAse free water was added to the mixture such that the final concentration of 411 
MOF was 20 mg/mL. Negative controls of naked siRNA and negative controls of MOF only, each with 412 
and without enzyme, were also prepared with the same concentration and relative amounts of siRNA and 413 
nNU-1000, respectively. The mixture was placed in a 37°C incubator for approximately 2.5 h. The 414 
samples containing MOF were centrifuged at 14000 rpm for 60 s, and the supernatant was removed. For 415 
those samples that were acting as a negative control for enzyme, 10 μL of NEB Buffer 2 (10x) and 82.5 416 
μL of RNAse free water were added to the samples. For the conditions testing enzyme protection, 10 μL 417 
of NEB Buffer 2 (10x), 72.5 μL of RNAse free water, and 10 μL of Shortcut RNAse III enzyme were 418 
added. All samples were mixed and incubated for 20 min at 37°C before the addition of 10 μL of 10x 419 
EDTA. In order to release the siRNAs from the MOF to run on a gel, 100 μL of 10x PBS was added to 420 
each sample, and the samples were vortexed until dispersed. Using a Zymo Oligo Clean & 421 
Concentrator™ kit, the samples were all purified to remove residue MOF or linker. A Novex 20% TBE 422 
polyacrylamide gel was loaded using 8 μL of the purified product of each sample and 2 μL of Hi-Density 423 
TBE Sample Buffer (5X). A dsRNA ladder (NEB #N0363S) was also run. The gel was run at 200V for 424 
45 min, after which it was soaked in 100 mL of dH2O with 10 uL of PAGE GelGreen™ (Biotium) for 425 
approximately 1.5 h. It was imaged using a Syngene G:Box. 426 
siRNA Location Analysis Prep for Fluorescence-lifetime Imaging Microscopy. Samples of nNU-427 
1000 (ca. 0.2 mg) were incubated at 37°C for 2.5 h with either 100 μL of nuclease free water, as a 428 
negative control, or 100 μL of 100 μM tagged siRNA. After loading, the samples were centrifuged at 429 
14000 rpm for 90 s, the supernatant was removed and used to measure a background, and 200 μL of 430 
DMEM without phenol red were added to each of the samples. For the enzyme-reacted sample, 100 μL 431 
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of the sample loaded with tagged siRNA was spun down again at 14000 rpm for 60 s. The supernatant 432 
was removed and 10 μL of Shortcut RNAse III enzyme was added along with 72.5 μL of RNAse free 433 
water, and 10 μL of NEB Buffer 2 (10x). This was incubated for 20 min at 37°C before the addition of 434 
10 μL of 10x EDTA. This entire sample was then spun down again at 14000 rpm for 60 s, after which 435 
the supernatant was removed, and 200 μL of DMEM without phenol red was added to the sample.  436 
Fluorescence-lifetime Imaging Microscopy. All samples were assayed on a home-built, confocal-based 437 
FLIM platform using time-correlated single photon counting (TCSPC). The equipment is a modified 438 
version of a published multiparametric imaging system51 and equipped with a 100x objective lens (UPLS 439 
Apo, 100x oil, 1.4NA, Olympus, Germany). A pulsed supercontinuum source (WL-SC-400-15, Fianium 440 
Ltd., UK, pulse width 6ps, repetition rate 40MHz) was used for excitation in conjunction with a tuneable 441 
filter (AOTFnC-400.650, Quanta Tech, New York, USA), an excitation filter FF01-474/27, and an 442 
emission filter FF01-542/27 (both from Semrock Inc., New York, USA). Photons were recorded in time-443 
tagged, time-resolved mode that permits sorting photons from each pixel into a histogram according to 444 
the arrival times after the last laser pulse. The laser intensity at the samples was 60 μW. The data were 445 
recorded by SPC-830 (Becker and Hickl GmBH, Germany). Photons were acquired for two minutes to 446 
make a single 256 X 256 FLIM image. The time-correlated single-photon counting (TCSPC) histograms 447 
for each pixel were fitted with a double exponential decay function using FLIMfit52. The longer lifetime 448 
component τ2 of the MOF fluorescence decay varied between different conditions and was plotted. 449 
Statistical analysis was carried out using one-way ANOVA followed by Dunnett’s multiple comparisons 450 
test in Graphpad Prism software (La Jolla, California, USA). 451 
Structured Illumination Microscopy (SIM) Imaging. HEK 293-mC cells were cultured before being 452 
seeded at a density of 75,000 cell/mL and 0.4 mL per well on an 8-well LabTek Dish (Thermo Fisher 453 
155409) for 1 d. Cells were then incubated with 1.875 μL per well of BacMam Early Endosome Stain 454 
overnight. The following day, the entire well contents were removed and the cells were incubated with 455 
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the different conditions for MOF prepared following the same protocol described in siRNA Adsorption 456 
and Subsequent Cofactor Addition, above. The cells were incubated with these different conditions for 457 
4 h. Post incubation, media was removed from each well, washed once with 1× PBS, and replaced with 458 
non-phenol red complete DMEM for SIM Imaging. Images of the samples were collected using a custom 459 
built 3-color Structured Illumination Microscopy (SIM) setup which we have previously described.53 460 
A60×/1.2NA water immersion lens (UPLSAPO 60XW, Olympus) focused the structured illumination 461 
pattern onto the sample. This lens also captured the samples’ fluorescence emission light before imaging 462 
onto an sCMOS camera (C11440, Hamamatsu). Laser excitation wavelengths used were 488 nm 463 
(iBEAM-SMART-488, Toptica), 561 nm (OBIS 561, Coherent), and 640 nm (MLD 640, Cobolt), to 464 
excite the fluorescence emission of MOF, early endosomes, and siRNA-tag, respectively. The laser 465 
intensity at the samples was between 10 and 20 W/cm2. Upon reconstruction, it was found that the 466 
intensity of signal of the MOF and siRNA was too low for artefact-free SIM reconstruction, so widefield 467 
reconstruction was used in these channels. SIM reconstruction for the endosome channel was performed 468 
in fairSIM,54 to utilise the latest developments in open-source SIM reconstruction. 469 
siRNA Efficacy Analysis. HEK 293 T-REx Flp-In cells with an inducible mCherry protein, referred to 470 
as HEK 293-mC cells, were cultured before being seeded at a density of 140,000 cell/mL with 1 mL per 471 
well on a 12-well Nunc Dish (ThermoFisher 150628) for approximately 24 h. The cells were activated 472 
with Tetracycline (final concentration: 1 μg/mL) and incubated overnight. While the cells were 473 
incubating, different conditions for MOF were prepared as described in siRNA Adsorption and 474 
Subsequent Cofactor Addition, above. 1 mL of complete DMEM media was added to each sample. The 475 
samples were sonicated for ca. 1 min. 200 μL of this solution was added to the respective wells. For the 476 
non-MOF conditions (Naked siRNA and siRNA@lipofectamine), 1 mL of complete DMEM media was 477 
added to each well prior to adding the following. For the Naked siRNA condition, 3 μL of 10 μM siRNA 478 
in a 1:2 ratio – tagged siRNA:untagged siRNA – was added to each well. For the siRNA@lipofectamine 479 
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condition, 50 μL of Opti-MEM™ Reduced Serum Medium GlutaMAX™ Supplement was mixed with 480 
3 μL lipofectamine in one tube, and 6 μL of 10 μM siRNA in a 1:2 ratio – tagged siRNA:untagged siRNA 481 
–in another tube. 50 μL of each solution was then combined and pipetted briefly before being incubated 482 
at room temperature for 5 min. After 5 min, 50 μL of this solution was added to each well. All conditions 483 
were left to incubate for 24 h. Post-condition incubation, the media was removed from each well, washed 484 
once with 1× PBS, once with trypan blue, twice more with 1× PBS, and then incubated for 5 min at 37 485 
°C with trypsin. Fresh complete DMEM without phenol red was added to the wells after trypsin 486 
incubation, and the entire contents were transferred to Eppendorf tubes and centrifuged at 1200 rpm for 487 
5 min. The cells were resuspended in 500 μL of complete DMEM without phenol red. Samples were 488 
measured immediately on a Cytek DxP8 analyser cytometer. Analysis was completed with FlowJo 489 
software (Becton, Dickinson & Company subsidiary) and Graphpad Prism software (La Jolla, California, 490 
USA). 491 
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